Ozempic, Wegovy, and Zepbound: What Cash-Pay Really Costs in 2026

Written By Dmitriy Grinberg
Disclaimer: This content is provided for informational and educational purposes only and is not intended as medical advice or a substitute for professional medical evaluation, diagnosis, or treatment. Reading this content does not establish a provider-patient relationship. Always seek the advice of your physician or other qualified healthcare provider regarding any medical concerns or conditions. Never disregard professional medical advice or delay seeking care because of something you have read here.
An open wallet with cash next to pills and a GLP-1 pen on a bright counter

For years, the hardest thing about a GLP-1 medication wasn’t the weekly injection. It was finding out what it would cost you.

Drugs like Ozempic and Wegovy carried retail prices of roughly $900 to $1,350 a month. Almost nobody paid that number, but almost nobody could see their real number either. What you actually owed depended on your plan, your pharmacy, a prior authorization, and a coverage decision that could change without warning. The price was a moving target you only hit at the register.

That’s starting to change. In 2026, the companies that make these drugs are selling them directly to patients at a printed cash price. For a brand of medicine that built its reputation on being impossible to afford, that’s a real shift — and it’s worth understanding before you assume one of these is out of reach.

What the cash price actually is right now

Here are the manufacturer self-pay numbers as of August 2026.

Through NovoCare, Novo Nordisk’s direct pharmacy, the self-pay price for Ozempic or Wegovy is $199 a month for your first two fills (an introductory offer running through December 31, 2026), then $349 a month after that for most doses. The higher-dose versions run more — up to about $499 a month for Ozempic 2 mg. The newer Wegovy pill starts around $149 a month for certain doses.

On the other side, Eli Lilly sells its GLP-1 drugs through LillyDirect. Zepbound runs roughly $299 to $499 a month depending on the dose, and Mounjaro is sold at a flat monthly price in a similar range.

The pattern is the same across both makers: a cash price that lands far below the old retail sticker, printed in plain dollars, with no insurance in the middle.

The honest part

We’re a direct-pay practice, so we like printed prices. But we’re not going to pretend a few hundred dollars a month is nothing.

At maintenance doses, a GLP-1 still adds up to more than $3,000 a year, every year, for as long as you take it. Stop taking it and much of the weight tends to return, so this is usually a long commitment, not a short course. That math matters, and it’s exactly the kind of number you want in front of you before you start, not after.

There’s also the medical side, which the checkout price can quietly skip over. A GLP-1 is a real medication with real side effects and real contraindications. It isn’t right for everyone who wants it, and it interacts with other conditions and prescriptions. A cash price makes the drug easier to buy; it doesn’t make it the right choice for your body. That decision belongs with an actual MD or DO who has looked at your history — not a web form that clears you in ninety seconds.

Why this is bigger than one drug

Step back from Ozempic for a moment, because the more interesting story is the model.

For most of modern medicine, the price of care has been deliberately invisible. You get the service, then you get the bill, and the number in between is a mystery until it lands. GLP-1 pricing is one of the first times a blockbuster drug has been sold to patients the way most things are sold — with the price on the label.

That’s the whole idea behind direct-pay medicine. When the cost is printed and the middleman is gone, you can do the math ahead of time. You can compare. You can decide whether something is worth it before you commit, instead of discovering the damage later. A GLP-1 with a posted cash price is a small preview of what care looks like when the patient can actually see what they’re buying.

What to do if you’re considering one

If you’re weighing a GLP-1, a few practical steps:

Start with a physician, not a pharmacy. The first question isn’t “how do I get it” — it’s “is this appropriate for me, and what should I expect.” Bring your full medical history and your other medications.

Compare the direct-pay price against whatever your insurance would actually charge after a prior authorization. Sometimes cash is cheaper and simpler; sometimes coverage still wins. You won’t know until you put both numbers side by side.

Plan for the long haul, not the introductory month. Look at the price after the first two fills, because that’s the number you’ll live with.

And ask about the whole plan, not just the drug — nutrition, muscle, follow-up, and how you’ll be monitored. The medication is one tool, not the entire treatment.

Here in the Los Angeles area, that first conversation is one we have often. We’ll give you the real cost and an honest read on whether a GLP-1 even fits your situation — before you spend a dollar.

Skip the insurance maze for that first visit — book a virtual consultation or a same-day house call with physician.

Sources

Dmitriy Grinberg
Previous

A UTI Shouldn't Cost $2,000: Where to Go for Everyday Care in Los Angeles